Duloxetine in the treatment of generalized anxiety disorder

References

• Grant BF, Hasin DS, Stinson FS et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol. Med.35, 1747–1759 (2005).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund PA, Demler O et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry62, 593–602 (2005).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Chiu WT, Demler O et al. Prevalence, severity, and co-morbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry62, 617–627 (2005).
   PubMed Web of Science ®Google Scholar
• Kroenke K, Spitzer RL, Williams JB, Monahan PO, Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann. Intern. Med.146, 317–325 (2007).
   PubMed Web of Science ®Google Scholar
• Munk-Jorgensen P, Allgulander C, Dahl AA et al. Prevalence of generalized anxiety disorder in general practice in Denmark, Finland, Norway, and Sweden. Psychiatr. Serv.57, 1738–1744 (2006).
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Kessler RC, Beesdo K, Krause P, Höfler M, Hoyer J. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J. Clin. Psychiatry63(Suppl. 8), 24–34 (2002).
   PubMed Web of Science ®Google Scholar
• Wang PS, Lane M, Olfson M, Pincus HA, Wells, KB, Kessler, RC. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch. Gen. Psychiatry62, 629–640 (2005).
   PubMed Web of Science ®Google Scholar
• Alonso J, Angemeyer MC, Bernert S et al. Disability and quality of life impact of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) Project. Acta Psychiatr. Scand. Suppl.420, 38–46 (2004).
   PubMedGoogle Scholar
• Mogotsi M, Kaminer D, Stein DJ. Quality of life in the anxiety disorders. Harv. Rev. Psychiatry8, 273–282 (2000).
   PubMed Web of Science ®Google Scholar
• Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress. Anxiety25, 72–90 (2008).
   PubMed Web of Science ®Google Scholar
• Buist-Bouwman MA, De Graaf R, Vollebergh WAM et al. Functional disability of mental disorders and comparison with physical disorders: a study among the general population of six European countries. Acta Psychiatr. Scand.113, 492–500 (2006).
   PubMed Web of Science ®Google Scholar
• McWilliams LA, Cox BJ, Enns MW. Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. Pain106, 127–133 (2003).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Dupont RL, Berglund P et al. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am. J. Psychiatry156, 1915–1923 (1999).
   PubMed Web of Science ®Google Scholar
• Bruce SE, Yonkers KA, Otto MW et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am. J. Psychiatry162, 1179–1187 (2005).
   PubMed Web of Science ®Google Scholar
• Yonkers KA, Warshaw MG, Massion AO, Keller MB. The phenomenology and course of generalized anxiety disorder. Br. J. Psychiatry.168, 308–313 (1996).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Gruber M, Hettema JM, Hwang I, Sampson N, Yonkers KA. Co-morbid major depression and generalized anxiety disorders in the National Comorbidity Survey follow-up. Psychol. Med.38, 365–374 (2008).
   PubMed Web of Science ®Google Scholar
• Lader MH. The nature and duration of treatment for GAD. Acta Psychiatr. Scand. Suppl.393, 109–117 (1998).
   PubMedGoogle Scholar
• Ashton H. Guidelines for the rational use of benzodiazepines: when and what to use. Drugs48, 25–40 (1994).
   PubMed Web of Science ®Google Scholar
• Ninan PT. The functional anatomy, neurochemistry, and pharmacology of anxiety. J. Clin. Psychiatry60(Suppl. 22), 12–17 (1999).
   PubMed Web of Science ®Google Scholar
• Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N. Engl. J. Med.328, 1398–1405 (1993).
   PubMed Web of Science ®Google Scholar
• van Laar M, Volkerts E, Verbaten M. Subchronic effects of the GABA-agonist lorazepam and the 5-HT2A/2C antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers. Psychopharmacology (Berl.)154, 189–197 (2001).
   PubMed Web of Science ®Google Scholar
• Wang PS, Bohn RL, Glynn RJ et al. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Am. J. Psychiatry158, 892–898 (2001).
   PubMed Web of Science ®Google Scholar
• Rickels K, Weisman K, Norstad N et al. Buspirone and diazepam in anxiety: a controlled study. J. Clin. Psychiatry43, 81–86 (1982).
   PubMed Web of Science ®Google Scholar
• Scheibe G. Four-year follow-up in 40 out-patients with anxiety disorders: buspirone versus lorazepam. Eur. J. Psychiatry10, 25–34 (1996).
   Google Scholar
• Davidson JRT, Dupont RL, Hedges D, Haskins JT. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J. Clin. Psychiatry60, 528–535 (1999).
   PubMed Web of Science ®Google Scholar
• Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone and diazepam. Arch. Gen. Psychiatry50, 884–895 (1993).
   PubMed Web of Science ®Google Scholar
• Allgulander C, Dahl AA, Austin C et al. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am. J. Psychiatry161, 1642–1649 (2004).
   PubMed Web of Science ®Google Scholar
• Brawman-Mintzer O, Knapp RG, Rynn M, Carter RE, Rickels K. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry67, 874–881 (2006).
   PubMed Web of Science ®Google Scholar
• Pollack MH, Zaninelli R, Goddard A et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J. Clin. Psychiatry62, 350–357 (2001).
   PubMed Web of Science ®Google Scholar
• Stocchi F, Nordera G, Jokinen RH et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J. Clin. Psychiatry64, 250–258 (2003).
   PubMed Web of Science ®Google Scholar
• Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am. J. Psychiatry160, 749–756 (2003).
   PubMed Web of Science ®Google Scholar
• Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int. J. Neuropsychopharmacol.9, 495–505 (2006).
   PubMed Web of Science ®Google Scholar
• Davidson JRT, Bose A, Korotzer A et al. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress. Anxiety19, 234–240 (2004).
   PubMed Web of Science ®Google Scholar
• Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br. J. Psychiatry179, 15–22 (2001).
   PubMed Web of Science ®Google Scholar
• Gelenberg AJ, Lydiard RB, Rudolph R et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA283, 3082–3088 (2000).
   PubMed Web of Science ®Google Scholar
• Kelsey JE. Efficacy, safety, and tolerability of venlafaxine XR in generalized anxiety disorder. Depress. Anxiety12(Suppl. 1), 81–84 (2000).
   PubMedGoogle Scholar
• Rickels K, Pollack MH, Sheehan DV, Haskins JT. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am. J. Psychiatry157, 968–974 (2000).
   PubMed Web of Science ®Google Scholar
• Sheehan DV. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder. J. Clin. Psychiatry60(Suppl. 22), 23–28 (1999).
   PubMedGoogle Scholar
• Ballenger JC, Davidson JRT, Lecrubier Y et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J. Clin. Psychiatry62(Suppl. 11), 53–58 (2001).
   PubMed Web of Science ®Google Scholar
• Goodman WK. Selecting pharmacotherapy for generalized anxiety disorder. J. Clin. Psychiatry65(Suppl. 13), 8–13 (2004).
   PubMedGoogle Scholar
• Vasile RG, Bruce SE, Goisman RM, Pagano M, Keller MB. Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobia. Depress. Anxiety22, 59–67 (2005).
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology25, 871–880 (2001).
   PubMed Web of Science ®Google Scholar
• Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J. Clin. Pharmacol.40, 161–167 (2000).
   PubMed Web of Science ®Google Scholar
• Skinner MH, Kuan HY, Pan A et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin. Pharmacol. Ther.73, 170–177 (2003).
   PubMed Web of Science ®Google Scholar
• Troelsen KB, Nielsen EO, Mirza NR. Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter. Psychopharmacology (Berl.)181, 741–750 (2005).
   PubMed Web of Science ®Google Scholar
• Detke MJ, Lu Y, Goldstein DJ et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J. Clin. Psychiatry63, 308–315 (2002).
   PubMed Web of Science ®Google Scholar
• Nutt DJ, Ballenger JC, Sheehan D, Wittchen HU. Generalized anxiety disorder: comorbidity, comparative biology and treatment. Int. J. Neuropsychopharmacol.5, 315–325 (2002).
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr. Scand.67, 361–370 (1983).
   PubMed Web of Science ®Google Scholar
• Lipman RS, Covi L. Outpatient treatment of neurotic depression: medication and group psychotherapy. In: Evaluation of Psychological Therapies. Spitzer R, Klein D (Eds). John Hopkins University Press, MD, USA 178–218 (1976).
   Google Scholar
• Raskin A, Schulterbrandt J, Reating N et al. Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives. J. Nerv. Ment. Dis.148, 87–98 (1969).
   PubMed Web of Science ®Google Scholar
• Guy W. The clinician global severity and impression scales. In: ECDEU Assessment Manual for Psychopharmacology. US Department Health, Education, and Welfare, MD, USA 218–222 (1976).
   Google Scholar
• Hamilton M. The assessment of anxiety states by rating. Br. J. Med. Psychol.32, 50–55 (1959).
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int. Clin. Psychopharmacol.11(Suppl. 3), 89–95 (1996).
   PubMed Web of Science ®Google Scholar
• Koponen H, Allgulander C, Erickson J et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim. Care Companion J. Clin. Psychiatry9, 100–107 (2007).
   PubMedGoogle Scholar
• Rynn M, Russell J, Erickson J et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress. Anxiety25, 182–189 (2008).
   PubMed Web of Science ®Google Scholar
• Hartford J, Kornstein S, Liebowitz M et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int. Clin. Psychopharmacol.22, 167–174 (2007).
   PubMed Web of Science ®Google Scholar
• Nicolini H, Bakish D, Duenas H et al. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychol. Med.19, 1–10 (2008).
   Google Scholar
• Allgulander C, Nutt D, Detke D et al. A noninferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder. J. Psychopharmacol.22, 417–425 (2008).
   PubMed Web of Science ®Google Scholar
• Nutt D, Allgulander C, Lecrubier Y, Peters T, Wittchen HU. Establishing non-inferiority in treatment trials in psychiatry – guidelines from an Expert Consensus Meeting. J. Psychopharmacol.22, 409–416 (2008).
   PubMedGoogle Scholar
• EMEA (1998) ICH Topic E9: Statistical principles for clinical trials (CPMP/ICH/363/96).
   Google Scholar
• Pollack MH, Kornstein SG, Spann ME et al. Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J. Psychiatr. Res.42(14), 1176–1184 (2008).
   PubMedGoogle Scholar
• Endicott J, Russell JM, Raskin J et al. Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies. J. Clin. Psychiatry68, 518–524 (2007).
   PubMed Web of Science ®Google Scholar
• Endicott J, Nee J, Harrison W et al. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol. Bull.29, 321–326 (1993).
   PubMed Web of Science ®Google Scholar
• EuroQol Group. EuroQol: a new facility for the measurement of health related quality of life. Health Policy16, 199–208 (1990).
   PubMed Web of Science ®Google Scholar
• Pollack MH, Endicott J, Liebowitz M et al. Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. J. Psychiatr. Res.42(12), 1042–1049 (2008).
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Meyers AL, Prakash A et al. The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder. Curr. Med. Res. Opin.24, 2457–2466 (2008).
   PubMed Web of Science ®Google Scholar
• Merikangas KR, Angst J, Isler H. Migraine and psychopathology: results of the Zurich cohort study of young adults. Arch. Gen. Psychiatry47, 849–853 (1990).
   PubMed Web of Science ®Google Scholar
• Olfson M, Gameroff MJ. Generalized anxiety disorder, somatic pain and health care costs. Gen. Hosp. Psychiatry29, 310–316 (2007).
   PubMed Web of Science ®Google Scholar
• Briley M. Clinical experience with dual action antidepressants in different chronic pain syndromes. Human Psychopharmacol.19(Suppl. 1), S21–S25 (2004).
   PubMed Web of Science ®Google Scholar
• Traub RJ. Spinal modulation of the induction of central sensitization. Brain Res.778, 34–42 (1997).
   PubMedGoogle Scholar
• Max MB. Antidepressant drugs as treatments for chronic pain: efficacy and mechanisms. In: Pain and the Brain: From Nociception to Cognition: Advances in Pain Research and Therapy (Volume 22). Bromm B, Desmedt JE (Eds). Raven Press Ltd, NY, USA 501–514 (1995).
   Google Scholar
• Brannan SK, Mallinckrodt CH, Brown EB et al. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J. Psychiatr. Res.39, 43–53 (2005).
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Lu Y, Detke MJ et al. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics45, 17–28 (2004).
   PubMed Web of Science ®Google Scholar
• Arnold LM, Lu Y, Crofford LJ et al. A double-blind, multicenter trial comparing duloxetine to placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum.50, 2974–2984 (2004).
   PubMed Web of Science ®Google Scholar
• Arnold LM, Rosen A, Lu Y et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain6, 5–15 (2005).
   Google Scholar
• Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain116, 109–118 (2005).
   PubMed Web of Science ®Google Scholar
• Wernicke J, Lu Y, D’Souza DN et al. Antidepressants: duloxetine at doses of 60 mg QD and 60 mg BID is effective in treatment of diabetic neuropathic pain (DNP). J. Pain5(3 Suppl. 1), S48 (2004).
   PubMedGoogle Scholar
• Hartford JT, Endicott J, Kornstein SG et al. Implications of pain in generalized anxiety disorder: efficacy of duloxetine. Prim. Care Companion J. Clin. Psychiatry10, 197–204 (2008).
   PubMedGoogle Scholar
• Davidson JRT, Allgulander C, Pollack MH et al. Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. Human Psychopharmacol.23, 519–526 (2008).
   PubMed Web of Science ®Google Scholar
• Davidson JRT, Wittchen HU, Llorca PM et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur. Neuropsychopharm.18, 673–681 (2008).
   PubMed Web of Science ®Google Scholar
• Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N. Engl. J. Med.358, 252–260 (2008).
   PubMed Web of Science ®Google Scholar
• Ruff D, Detke MJ, Robinson MJ. Problems with indirect comparisons in meta-analyses. BMC Psychiatry7, (2007).
   Google Scholar
• Papakostas GI, Thase ME, Fava M et al. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol. Psychiatry62, 1217–1227 (2007).
   PubMed Web of Science ®Google Scholar
• Kim TS, Pae CU, Yoon SJ et al. Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder. Psychiatry Clin. Neurosci.60, 347–351 (2006).
   PubMedGoogle Scholar
• Ruscio AM, Chiu WT, Roy-Byrne P et al. Broadening the definition of generalized anxiety disorder: effects on prevalence and associations with other disorders in the National Comorbidity Survey Replication. J. Anxiety Disord.21, 662–676 (2007).
   PubMed Web of Science ®Google Scholar